- Idera Pharmaceuticals (NASDAQ:IDRA) perks up 4% premarket on modest volume on the heels of its announcement of updated data from a Phase 1/2 clinical trial assess the combination of intratumoral IMO-2125 and Bristol-Myers Squibb's (NYSE:BMY) YERVOY (ipilimumab) in patients with metastatic melanoma who failed to respond to a PD-1 inhibitor. The results will be presented on Saturday, November 11 at the Concurrent Session 207: Clinical Trials: Novel Combinations at the 2017 Society for Immunotherapy of Cancer Annual Meeting in National Harbor, MD.
- A fifth (unconfirmed) response has been observed in 10 evaluable patients to date, implying a 50% response rate.
- IMO-2125 is an agonist of endosomal Toll-like receptor (TLR) 9, a cell surface protein that plays a key role in pathogen recognition and innate immunity.
- H.C. Wainwright has initiated coverage with a Buy rating and $4 price target.
- Previously: Idera Pharma's IMO-2125 shows encouraging action in early-stage melanoma study; shares ahead 15% premarket (Sept. 11)
- Now read: An Upcoming Conversation With An Expert: Preparing For Revance Therapeutics' Phase 3 Pivotal Trial Data Releases In Q4 2017
Original article